William Blair, Charles River Laboratories

Charles River Laboratories International (NYSE:CRL) Downgraded by William Blair to Market Perform
Charles River Laboratories International (NYSE:CRL – Get Free Report) was downgraded by equities research analysts at William Blair from an “outperform” rating to a “market perform” rating in a report released on Wednesday,
William Blair cuts Charles River Labs stock rating to Market Perform
William Blair analysts downgraded shares of Charles River Laboratories International Inc. (NYSE:CRL) stock from Outperform to Market Perform. The decision comes amid growing concerns about the company's near-term prospects,
Charles River downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Charles River (CRL) to Market Perform from Outperform without a price target “There is simply too much working
Charles River Laboratories International’s (CRL) “Neutral” Rating Reiterated at UBS Group
UBS Group reaffirmed their neutral rating on shares of Charles River Laboratories International (NYSE:CRL – Free Report) in a research note released on Friday morning, MarketBeat reports. They currently have a $185.
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors
This was the stock's second consecutive day of losses.
Hold Rating for Charles River Labs Amid Supply Chain Challenges and Mitigation Strategies
Mizuho Securities analyst Ann Hynes has maintained their neutral stance on CRL stock, giving a Hold rating yesterday.Stay Ahead of the
Charles River Labs downgraded at William Blair on less early-stage R&D spending
William Blair downgraded Charles River Laboratories to market perform from outperform citing a likely decline in early-stage R&D spending from large pharmaceutical companies. Analysts Max Smock and Christine Rains said that they are concerned about the near-term outlook for the contract research organization "given our view that in light of the
Charles River Laboratories Stock Falls 6% on Dim FY25 Outlook
Shares for Charles River Laboratories slipped after the company said it expects revenue to decline in 2025. Shares of the Massachusetts-based pharmaceutical company were recently down 6% to $178.50 in morning trading. The stock is about 35% below its 52-week peak of $275.
Barchart on MSN4h
Charles River Laboratories' Quarterly Earnings Preview: What You Need to Know
Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical ...
What Analysts Are Saying About Charles River Stock
Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...
Charles River CEO reveals drop in 2025 revenue outlook at JP Morgan
At the JP Morgan Healthcare Conference 2025, Charles River CEO blamed low client spending, loss of a contract and other ...
Charles River Labs: Near A Fundamental Trough, Growth Should Reignite Again
In Upslope’s view, CRL is a cyclical compounder going through a…cyclical downturn. Why are we bullish CRL stock? Click here ...
Morningstar2d
Charles River Laboratories International Inc CRL
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
TMCnet3d
Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
Apollo for Biologics: Provides a centralized platform to submit sample submission forms, track samples, and exchange documents all in one place, ensuring accuracy and saving time.
Hosted on MSN2d
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises
Charles River Laboratories International, Inc. CRL has introduced Apollo for CRADL (Charles River Accelerator and Development Lab), a secure cloud-based platform that enhances leading vivarium rental ...